Navigation Links
Promising new West Nile therapy cures disease in mice

West Nile virus alarmed Americans when it made its first U.S. appearance in New York City in 1999. It has since spread from coast to coast, sickened more than 16,000 Americans and killed more than 600. As the virus spread, medical investigators hastened research to develop an effective vaccine or therapy. None currently exist, but a newly published paper by researchers at Washington University in St. Louis points to a promising treatment. This research, published today online by Nature Medicine, was funded in part by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The research team developed an infection-fighting antibody that mimics one produced by people whose immune systems successfully fend off the West Nile virus. The researchers tested their antibody in mice and say its success warrants further development and testing in people with West Nile disease.

"West Nile virus has emerged in the United States as a regular seasonal threat, particularly for people over 50. We currently do not have a proven therapy for people with serious West Nile disease, so we will continue to aggressively pursue all promising leads for an effective treatment," says Anthony S. Fauci, M.D., director of NIAID.

Scientists do not know why some people infected with West Nile virus have no symptoms or a mild flu-like illness, while in others the virus invades the central nervous system and causes paralysis or coma. "We could give this antibody to mice as long as five days after infection, when West Nile virus had entered the brain, and it could still cure them," says Washington University senior investigator Michael Diamond, M.D., Ph.D., who headed the research team, which is supported in part by the NIAID-funded Midwest Regional Center of Excellence for Biodefense and Emerging Infectious Diseases. "It also completely protected the mice against death."

The researchers decided to develop the potential
'"/>

Source:NIH


Page: 1 2

Related biology news :

1. Another Look Finds Promising Proteomics Test is Not Biologically Plausible
2. Promising therapies for haemophilia & heart disease
3. Promising cell protein may play role in infection and dry eye
4. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
5. Columbia research lifts major hurdle to gene therapy for cancer
6. Combination therapy boosts effectiveness of telomere-directed cancer cell death
7. Gene therapy converts dead bone graft to new, living tissue
8. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
9. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
10. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
11. New therapy for HIV/AIDS eliminates needles and excessive toxicity
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Promising new West Nile therapy cures disease mice

(Date:1/22/2015)... CHARLOTTE, N.C. , Jan. 22, 2015 Infinisource has ... introduction of the G2 model. The G2 sets a higher ... company,s iSolved human capital management solution. With plug-and-play installation, touch ... G2 time clock provides a robust time collection solution for ...
(Date:12/22/2014)... Dec. 22, 2014  The 2014 Holiday Season may be ... Market Intelligence reports that the long anticipated floodgates for ... intensifying demand for smart phones, tablets, and wearable mobile ... of 2.5 billion users with nearly 4.8 billion biometric ...
(Date:12/19/2014)... LAS VEGAS , Dec. 18, 2014   LaunchKey ... built for the post-password and Internet of Things era, ... seed funding. The venture round was led by Metamorphic ... Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has ...
Breaking Biology News(10 mins):Infinisource's NXG series sets new time clock standard 2First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... Mass. CellThera, a biotechnology company located in ... at Gateway Park, has received a contract from ... to extend its research program in tissue regeneration. ... is part of WPI,s Bioengineering Institute (BEI), and ...
... the Helmholtz scientists and their clinical partners want to ... disease and gain perspectives for early diagnosis and therapy. ... online in the journal Nature Genetics . ... (QT Interval and Sudden Cardiac Death), Dr. Arne Pfeufer ...
... are used to thinking of heart disease as a product ... eat and how much we exercise. There is another road ... increase in particulate air pollution is associated with an increase ... relatively new field of environmental cardiology -- a field that ...
Cached Biology News:CellThera and WPI advance in regeneration study 2Genetic risk factors identified for sudden cardiac death 2Genetic risk factors identified for sudden cardiac death 3Inhaling a heart attack: How air pollution can cause heart disease 2Inhaling a heart attack: How air pollution can cause heart disease 3
(Date:1/22/2015)... (PRWEB) January 22, 2015 The laboratory ... that has witnessed a number of technological advancements due ... regulatory requirements, growing need to integrate healthcare systems, and ... ease challenges in system integration. Key players in the ...
(Date:1/22/2015)... January 22, 2015 Dr. Greg Leyer of ... annual Scripps Natural Supplements Pre-Conference seminar on probiotics in San ... an annual continuing education conference for health care professionals. This ... the topic of probiotics in health. Dr. Leyer spoke about ...
(Date:1/22/2015)... Jan. 22, 2015   Cypher Genomics, Inc., ... (NASDAQ: SQNM ), the leading molecular ... next generation noninvasive prenatal tests (NIPT). Through this ... called Mantis™, to advance analysis of clinically-relevant fetal ...
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval ... for the use of Medtronic,s SynchroMed ® II ... for use with United Therapeutics, Remodulin ® (treprostinil) ...
Breaking Biology Technology:Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... Technology to Find a Faster, More Accurate ... 1 ChemImage, ( www.chemimage.com ) today ... Breath, LLC ( www.nextbreath.net ), a leading ... ChemImage,s Raman Chemical Imaging for bioequivalence applications ...
... PETACH TIKVA, Israel, April 1 NexGen Biofuels,Ltd. ... a non-binding,Letter of Intent with World Venture Management ... ("WVM" ) and Mac Bioventures, Inc. The transaction,includes ... relating to its Real,Estate acquisitions and asset management ...
... 1 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), ... and oils in plant seeds, provides an ... insulin program. In December 2008, SemBioSys announced ... to license rights to SemBioSys, proprietary plant-produced ...
Cached Biology Technology:ChemImage and Next Breath Structure Partnership to Validate Bioequivalence Testing for Nasal Spray Suspensions 2ChemImage and Next Breath Structure Partnership to Validate Bioequivalence Testing for Nasal Spray Suspensions 3NexGen Biofuels Ltd Signs Letter of Intent for the Purchase of World Venture Management, Inc. Assets and the Sale of its Current Business 2SemBioSys provides update on insulin program 2SemBioSys provides update on insulin program 3
Rabbit polyclonal to Survivin DEx3 ( Abpromise for all tested applications). entrezGeneID: 332 SwissProtID: O15392...
Anti-Mouse C-10, Biotin (Polyclonal) (rabbit IgG)...
Goat polyclonal to SART3 ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSNADFAKLFLRK, corresponding to C terminal amino acids 951-963 of Human SART3 Entrez Gene ID: 9...
... The FastPlax Antibody is used to ... on the surface of infected cells as ... the basis of the FastPlax Titer Kit, ... just 25-48 hours. The FastPlax ...
Biology Products: